Why WindRose Health Investors Is Buying CardioOne

By Amit Chowdhry • Mar 5, 2024

WindRose Health Investors – a New York-based healthcare private equity firm – announced it has completed the acquisition of CardioOne, a physician enablement company built specifically to serve independent cardiologists. And CardioOne enables cardiologists to thrive today while preparing them for the future of value-based care.

The company offers physicians with an integrated technology platform, a practice optimization program, a workforce solution, and a growth engine that combines to provide a best-in-class patient and provider experience. The terms of the transaction were not disclosed.

WindRose worked with with CardioOne’s executive team to acquire the business and to provide up to $100 million of additional capital to support the company’s ongoing growth. And with WindRose’s investment, CardioOne will accelerate its next phase of expansion and enhance its existing service offerings. CardioOne’s current management team will continue to lead the company and remain active shareholders going forward.

McDermott Will & Emery LLP and Bass, Berry & Sims PLC acted as legal advisors to WindRose. And Kastner Gravelle LLP acted as legal advisor to CardioOne.

KEY QUOTES:

“We are excited for the opportunity to partner with WindRose as CardioOne embarks on its next chapter of growth. We believe that working with WindRose, which has a history of successfully partnering with companies to help navigate the transition to value-based care, will empower us to continue supporting independent cardiologists while developing additional solutions that maximize each practice’s potential in the shift to VBC arrangements.”

  • Jasen Gundersen MD, CardioOne’s Chief Executive Officer and co-founder

“CardioOne’s unique, physician-aligned model meets the market where it is and positions the Company to take advantage of the growing desire among cardiologists to maintain their independence. We believe CardioOne delivers a compelling tech-enabled offering to the independent cardiology market and has significant growth potential as the company builds upon its momentum in 2023. We are excited to join forces with Jasen and his team as they continue to build upon the differentiated platform they have created.”

  • Oliver Moses, Managing Partner with WindRose